The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Nano Regulatory News (ONT)

Share Price Information for Oxford Nano (ONT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 110.10
Bid: 110.20
Ask: 111.40
Change: 3.70 (3.48%)
Spread: 1.20 (1.089%)
Open: 105.40
High: 113.90
Low: 104.60
Prev. Close: 106.40
ONT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

29 Feb 2024 18:00

RNS Number : 0548F
Oxford Nanopore Technologies plc
29 February 2024
 

29 February 2024

Oxford Nanopore Technologies plc

("Oxford Nanopore" or the "Company")

Directorate Change

Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new generation of nanopore-based molecular sensing technology, today announces the retirement of three Directors from the Board: Dr James ("Spike") Willcocks, Clive Brown, and Tim Cowper. Clive will step off the Board with immediate effect while Spike and Tim will not stand for re-election at the 2024 AGM and will retire from the Board at the conclusion of the AGM in June 2024. All three Directors will remain in their operational leadership roles at Oxford Nanopore: Spike as Chief Strategy Officer, Clive as Chief Technology, Innovation and Product Officer and Tim as Chief Operating Officer. Each will also continue to serve on the Company's Operating Committee.

These changes are part of normal Board evolution and in line with best practice governance.

Spike has served on the Board for 18 years and Clive and Tim have each served for five years.

Duncan Tatton-Brown, Chair of Oxford Nanopore, commented: "I would like to thank Spike, Clive and Tim for their outstanding support and contribution to the Board during their long tenure and specifically in the transition period since IPO. They have played a foundational role in building this Company, and we are grateful for their ongoing dedication and leadership."

As before and in line with the Company's delegation of authority, the Company has determined that only Directors are Persons Discharging Managerial Responsibilities (PDMRs). Following retirement from the Board, Clive, Spike and Tim will no longer be PDMRs.

Oxford Nanopore is committed to Board diversity, and this evolution will also progress towards fulfilling the Company's goal of reaching 40% female Board representation. Following the AGM, the Board will include two executive Directors and seven non-executive Directors, three of whom are women.

This announcement is made pursuant to Listing Rule 9.6.11R.

 

[ENDS]

 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors: ir@nanoporetech.com

Media: media@nanoporetech.com

 

Teneo

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPPUBCPUPCGMB
Date   Source Headline
1st May 20245:00 pmRNSIssue of Equity and Total Voting Rights
1st May 20247:00 amRNSDirector/PDMR Shareholding
30th Apr 20247:00 amRNSPublication of Annual Report and Notice of AGM
12th Apr 20241:00 pmRNSStudy unlocks insights into disease and longevity
12th Apr 202412:00 pmRNSLTIP and DBP; Director/PDMR Notification
11th Apr 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
8th Apr 20244:00 pmRNSBlock Listing Interim Review
2nd Apr 20242:00 pmRNSIssue of Equity and Total Voting Rights
28th Mar 20245:55 pmRNSHolding(s) in Company
12th Mar 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
12th Mar 20247:00 amRNSOxford Nanopore to Present at Barclays Conference
8th Mar 202412:00 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirector/PDMR Shareholding
6th Mar 20247:00 amRNSFY23 Preliminary Results
1st Mar 20242:00 pmRNSIssue of Equity and Total Voting Rights
29th Feb 20246:00 pmRNSDirectorate Change
13th Feb 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
2nd Feb 20244:30 pmRNSHolding(s) in Company
1st Feb 202412:00 pmRNSIssue of Equity and Total Voting Rights
22nd Jan 20247:00 amRNSExpansion of leadership team
11th Jan 20245:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
11th Jan 20245:30 pmRNSEmployee Stock Purchase Plan - PDMR Notification
9th Jan 20247:00 amRNSFY23 trading update
3rd Jan 20247:00 amRNSPresentation at 42nd Annual J.P. Morgan Conference
19th Dec 20232:00 pmRNSAppointment of Two Non-Executive Directors
12th Dec 20235:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
7th Dec 20234:30 pmRNSNanopore Community Meeting Technology Update
1st Dec 20235:00 pmRNSIssue of Equity and Total Voting Rights
30th Nov 20237:00 amRNSNational Australian rare disease programme
13th Nov 20235:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
13th Nov 202312:00 pmRNSParticipation in upcoming investor conferences
7th Nov 20238:30 amRNSAdmission to Trading on the London Stock Exchange
6th Nov 20237:00 amRNSIssue of Equity
1st Nov 20234:00 pmRNSIssue of Equity and Total Voting Rights
31st Oct 20237:00 amRNSApple showcases Oxford Nanopore in M3 launch
26th Oct 20236:10 pmRNSHolding(s) in Company
24th Oct 202312:30 pmRNSHolding(s) in Company
23rd Oct 20238:30 amRNSIssue of Equity and Total Voting Rights
23rd Oct 20238:30 amRNSAdmission to Trading on the London Stock Exchange
19th Oct 20237:00 amRNSCapital Markets Day - ONT expands into clinical
19th Oct 20237:00 amRNSbioMérieux makes investment in Oxford Nanopore
19th Oct 20237:00 amRNSMayo Clinic and Oxford Nanopore collaboration
11th Oct 20233:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
6th Oct 20233:00 pmRNSBlock Listing Interim Review
2nd Oct 20234:00 pmRNSIssue of Equity and Total Voting Rights
27th Sep 20235:00 pmRNSDirector Declaration
12th Sep 20233:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
12th Sep 20237:00 amRNSPresentation at the Morgan Stanley Conference
6th Sep 20237:00 amRNSInterim results for the 6 months ended 30 June 23
1st Sep 20233:00 pmRNSIssue of Equity and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.